Clinical trial
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ…
NCT00104676 · UNICANCER, Other · Completed
Key facts
| NCT number | NCT00104676 |
|---|---|
| Title | Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors |
| Official title | A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors |
| Lead sponsor | UNICANCER, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor |
| Intervention type | Biological, Drug |
| Interventions | bleomycin sulfate, cisplatin, etoposide, ifosfamide, oxaliplatin, paclitaxel |
| Enrollment | 263 |
| Start date | Nov 26, 2003 |
| Primary completion | Mar 29, 2012 |
| Completion | Feb 8, 2023 |
| First posted | Mar 4, 2005 |
| Last update posted | Feb 6, 2025 |
| Countries | France, Slovakia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: